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Going both from the organism to the DNA and from
the DNA to the organism, the biology of the 20th cen-
tury has paved the way for a new type of biologist who has
emerged from the laboratory during the last two decades:
the gene therapist. At the beginning of the nineties, much
of this young ﬁeld was based on a relatively simple con-
cept: a deﬁcient function can be replaced with an arti-
ﬁcial gene. For twenty years now, gene therapists have
been learning how wide the gap is between a concept and
its practical reality. However, according to the increasing
numbers of papers published which relate to gene ther-
apy, and the huge interest generated by meetings of the
American or the European Society of Gene Therapy, we
are certainly learning a lot.
So, what have we learnt? Firstly, biotechnology is
the key to link the bench to the bed of the patient.
The biotechnology industry is ideally placed to deal with
the concept of biotherapeutics and the range of manu-
facturing issues including good manufacturing practice
(GMP), safety, toxicology, product scale-up to generate
large batches of vectors, and testing new gene transfer
tools. The close contacts between biotech companies and
the development of gene therapy highlight the technolog-
ical aspects of gene therapy. Indeed, delivery of the gene
therapy has emerged as essential area for improvement.
Gene delivery is a major growth industry with approaches
ranging between almost-naked DNA to miniviruses and
viral vectorsguttedof most if not allof the viralsequences
of their original genome. In addition, there has been in-
creased and imaginative use of unexpected viruses as gene
transferagents,ashighlightedbyN.Maitlandetalintheir
reviewofbaculovirustotransfertherapeuticgenes.Where
is the universal vector everybody was running after 10
years ago?
We have also learned that between the needle and
the arm of the patient there is a world called “Biosafety.”
There is no “zero risk” when considering a biotherapeu-
tical strategy. In addition, gene therapy is a complex bi-
ological issue which generates speciﬁc risks as recently
evidenced during the treatment of genetic diseases with
adenoviral and retroviral vectors. It can be suggested that
gene therapy is not toxic because gene therapy is not ef-
ﬁcient. This opinion may hold some truth, but the use of
increasing doses, the use of more complex strategies, and
the use of more potent genetic activities is now leading us
to reach the borderline between safety and toxicity mak-
ing the biosafety a major determinant in the future of this
therapeuticalapproach.Biosafetyhastoconsiderboththe
design of a gene transfer product and the possibility for
this product to bypass the safety keys set up by the in-
vestigator to avoid the induction of unexpected deleteri-
ous eﬀects. In this respect, in this two-part special issue
T. Robson and D. G. Hirst (part II) focus on transcrip-
tional targeting and A. G. Sch¨ atzlein (part II) focuses on
the targeting of synthetic gene delivery. These reviews dis-
cuss one of the most important aspects of biosafety: the
possibility to restrict the expression of the gene of inter-
est to the selected tissue. In addition, A. Van den Broeke
and A. Burny (part I) remind us that gene transfer vec-
tors have to be considered in appropriate animal models
by taking advantage of an elegant sheep model that allow
us to revisit the concept of retroviral vector stability and
recombination potential.
We learned that there is not always a simple solu-
tion. Cardiovascular disease is a complex multiparame-
ter disorder. However, innovative biological therapies as
discussed by K. L. Dishart et al (part II) highlight some
very exciting advances in the ﬁeld of cardiovascular dis-
ease. It will be of interest over the next few years to an-
alyze whether clinical results will reach the expectations
in this domain bearing in mind the lessons of gene ther-
apy for cancer. The treatment of cancer, makes up almost
60 to 70% of the gene therapy trials worldwide, and in-
cludes some very elegant approaches (reviewed by D. H.
Palmer et al and by S. M. Scholl et al (part I)). Neverthe-
less,genetherapyforcancerremainsachallengingissueto
address despite 15 years of eﬀort and experience as exem-
pliﬁed by the gene therapy of malignant glioma (T. Kan-
zawaetal(partI))andpediatriccancer(E.Biagietal(part
I)). Improvements however, can be reassured through our
understanding of tumour biology and advances in chem-
istry. Examples of such improvements involve the synergy2 Nicol Keith and Claude Bagnis 2003:1 (2003)
between therapeutical strategies (R. J. Mairs and M. Boyd
(part II)), the use of cascade mechanisms such as strong
bystander eﬀects (W. A. Denny (part I)), or the boosting
of the immune system (S. M. Scholl et al (part I)). The
possibility to target the expression of a gene at the desired
time and location as reviewed in this issue will obviously
help us to improve the therapeutic impact of these ap-
proaches.
Measuring the success of a new therapy is a chal-
lenge in itself. The traditional criteria used to evaluate
cancer therapies may not be applicable to molecularly
driven therapeutics. As we enter the era of mechanism-
based therapeutics, it will be essential to show that the
new genetic therapies reach their desired target and in-
teracts with the target in a speciﬁc fashion. An essential
part of this process is therefore the development of new
approaches to visualize the localization of the transgene
and the extent of its eﬀects. The green ﬂuorescent protein
or the bacterial beta-galactosidase encoded by the LacZ
gene gave some insight to product localization. But mov-
ing into animal models highlights the need for new detec-
tiontechnologiessuchashighsensitivitydetectionoflight
and PET imaging. These advances in noninvasive imaging
in vivo are discussed by G. Vassaux and T. Groot-Wassink
(part II). This is an emerging ﬁeld which faces the chal-
lenge of detecting and mapping a few if not single cells, in
a 3D context in the next two decades. A nice bet.
Finally, it is encouraging that individual groups
worldwide are addressing local requirements to ensure
the progress of ﬂedgling genetic therapies into the clinic.
However, it is becoming clear that a greater cooperation
and uniﬁcation of regulatory procedures would enhance
the prospects of successful clinical trials for gene therapy.
Amati et al discuss how this might be achieved within Eu-
rope; a major but worthwhile task.
In summary, we learned a lot over the past twenty
years. It is a particularly exciting time to be involved
in gene therapy. There has been immense progress in
the ﬁeld and a realistic expectation that gene therapy
will make a diﬀerence to the patient. However, we still
have much to learn and this is one of the goals of this
two-part special issue on gene therapy of the Journal of
Biomedicine and Biotechnology.
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